239 related articles for article (PubMed ID: 37026381)
1. Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia.
Han JJ
Blood Res; 2023 Apr; 58(S1):S58-S65. PubMed ID: 37026381
[TBL] [Abstract][Full Text] [Related]
2. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
3. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
[No Abstract] [Full Text] [Related]
4. Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26
Pacelli P; Santoni A; Sicuranza A; Abruzzese E; Giai V; Crugnola M; Annunziata M; Galimberti S; Iurlo A; Luciano L; Sorà F; Fava C; Bestoso E; Marzano C; Cartocci A; Defina M; Sammartano V; Cencini E; Raspadori D; Bocchia M
Front Pharmacol; 2023; 14():1194712. PubMed ID: 37305536
[No Abstract] [Full Text] [Related]
5. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
Mahon FX; Boquimpani C; Kim DW; Benyamini N; Clementino NCD; Shuvaev V; Ailawadhi S; Lipton JH; Turkina AG; De Paz R; Moiraghi B; Nicolini FE; Dengler J; Sacha T; Takahashi N; Fellague-Chebra R; Acharya S; Wong S; Jin Y; Hughes TP
Ann Intern Med; 2018 Apr; 168(7):461-470. PubMed ID: 29459949
[TBL] [Abstract][Full Text] [Related]
6. [Chronic myeloid leukemia: aiming for treatment free remission].
Kimura S
Rinsho Ketsueki; 2021; 62(6):572-581. PubMed ID: 34219083
[TBL] [Abstract][Full Text] [Related]
7. Second-Generation Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia Patients with Stable Deep Molecular Response: A Systematic Review and a Meta-Analysis.
Di Q; Deng H; Zhao Y; Li BY; Qin L
Comput Math Methods Med; 2021; 2021():3110622. PubMed ID: 34956393
[TBL] [Abstract][Full Text] [Related]
8. SOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML).
Mikhaeel S; Atallah E
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):333-339. PubMed ID: 36934065
[TBL] [Abstract][Full Text] [Related]
9. Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety.
Laganà A; Scalzulli E; Bisegna ML; Carmosino I; Ielo C; Costa A; Torrieri L; Totaro M; Martelli M; Breccia M
Expert Opin Drug Saf; 2024 Jun; ():1-11. PubMed ID: 38873693
[TBL] [Abstract][Full Text] [Related]
10. Budget Impact of Treatment-Free Remission in Treating Chronic-Phase Philadelphia-Positive Chronic Myeloid Leukemia in Lebanon.
Elias F; Gebran A; Said C; Beker RV; Ammar W
J Glob Oncol; 2019 Jun; 5():1-7. PubMed ID: 31166826
[TBL] [Abstract][Full Text] [Related]
11. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
12. Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.
Hughes A; Yong ASM
Front Immunol; 2017; 8():469. PubMed ID: 28484463
[TBL] [Abstract][Full Text] [Related]
13. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
[TBL] [Abstract][Full Text] [Related]
14. Deep molecular responses for treatment-free remission in chronic myeloid leukemia.
Dulucq S; Mahon FX
Cancer Med; 2016 Sep; 5(9):2398-411. PubMed ID: 27367039
[TBL] [Abstract][Full Text] [Related]
15. Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?
Saifullah HH; Lucas CM
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439327
[TBL] [Abstract][Full Text] [Related]
16. Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings.
Cheng F; Li Q; Cui Z; Hong M; Li W; Zhang Y
Front Oncol; 2023; 13():1146108. PubMed ID: 37091188
[TBL] [Abstract][Full Text] [Related]
17. A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.
Webster JA; Robinson TM; Blackford AL; Warlick E; Ferguson A; Borrello I; Zahurak M; Jones RJ; Smith BD
Leuk Res; 2021 Dec; 111():106737. PubMed ID: 34768161
[TBL] [Abstract][Full Text] [Related]
18. Contemporary treatment methods of adult patients with BCR/ABL1 positive chronic myeloid leukemia.
Slezáková K; Mistrík M; Bátorová A
Vnitr Lek; 2020; 66(4):214-224. PubMed ID: 32972178
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
[TBL] [Abstract][Full Text] [Related]
20. Management of chronic myeloid leukemia in 2023 - common ground and common sense.
Senapati J; Sasaki K; Issa GC; Lipton JH; Radich JP; Jabbour E; Kantarjian HM
Blood Cancer J; 2023 Apr; 13(1):58. PubMed ID: 37088793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]